An observational study in Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis and Secondary Progressive Multiple Sclerosis, sponsored by University Hospital, Strasbourg, France. Completed at 1 site in France. Open to participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2026-10-06.
Sponsored by University Hospital, Strasbourg, France · Observational
The objective of the study is to evaluate the effectiveness of CladT, in terms of disease stability and safety, as the last treatment option in ageing MS patients vs treatment continuation and discontinuation This observational study will use database from local cohorts (from France, Belgium, Switzerland). Patients included must meet the inclusion criteria: RRMS diagnosis for more than 10 years without secondary progression, no evidence of disease activity (no relapse, no new MRI lesion, no EDSS progression) for more than 5 years under a DMT, age≥ 45-year-old.
Analyses will be using dynamic propensity score to match patients who stopped treatment with patients who had the same probability of continuing / stopping current treatments but took CladT as exit therapy. Patients with a minimum of 24 months follow up will be included.
The investigators will ensure that CladT provide disease stability compared to treatment continuation / discontinuation in ageing MS patients by measuring:
3,264 studies on the registry are indexed under Multiple Sclerosis; 659 are open to participants now.
This study's enrollment of 450 is above the median of 100 across 970 observational studies indexed under Multiple Sclerosis.
Browse Multiple Sclerosis studies →University Hospital, Strasbourg, France is the lead sponsor of 999 studies on the registry; 358 are open to participants now.
Counted across the registry records on this site, refreshed daily.
This is a multicentric retrospective and controlled cohort with non-inferiority analysis. Patients will be matched 1:1 using propensity score on gender, age, MS duration, time before last relapse, EDSS score, DMTs.
The study will use retrospectively collected data within the date frame from 06/30/25 to 06/30/26.
Approximately 150 patients treated with cladribine will be identified and included in this study in 7 centers: Strasbourg, Lille, Montpellier, Nimes, Liège, Pelt, Lugano.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: Cladribine
To evaluate the clinical activity during the 2 years of follow-up in patients switching to cladribine and continuing current DMT
To evaluate the clinical activity during the 2 years of follow-up in patients switching to cladribine and continuing current DMT
Proportion of patients with relapses\* and time to event during the 2 years of follow-up in patients switching to cladribine and continuing current DMT
Time frame: 2 years
To evaluate the clinical activity during the 2 years of follow-up in patients switching to cladribine and stopping current DMT
Proportion of patients with relapse and time to event during the 2 years of follow-up in patients switching to cladribine and stopping current DMT
Time frame: 2 years
To evaluate the clinical activity during the 3 years of follow-up in patients switching to cladribine and continuing current DMT
Proportion of patients with relapse and time to event during the 2 years of follow-up in patients switching to cladribine and continuing current DMT
Time frame: 2 years
To evaluate the radiological activity during the follow-up in patients switching to cladribine, continuing current DMT and stopping DMT
Proportion of patients with new T2 lesions on brain MRI at 1 and 2 years in patients switching to cladribine, continuing current DMT and stopping DMT
Time frame: 2 years
To evaluate the disability during the follow-up in patients switching to cladribine, continuing current DMT and stopping DMT
Proportion of patients with EDSS worsening\*\* after 2 years in patients switching to cladribine, continuing current DMT and stopping DMT
Time frame: 2 years
To evaluate the risk of serious adverse events in patients switching to cladribine and continuing current DMT
Proportion of patients with any serious adverse events after 2 years in patients switching to cladribine and continuing current DMT
Time frame: 2 years
Plan to share: Undecided
No publications or documents are linked to this record.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Strasbourg, France →